Vontobel Holding Ltd. grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 56.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,458 shares of the biopharmaceutical company's stock after acquiring an additional 2,322 shares during the quarter. Vontobel Holding Ltd.'s holdings in Regeneron Pharmaceuticals were worth $4,600,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. Rakuten Securities Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the third quarter worth $26,000. Fairfield Financial Advisors LTD acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $37,000. Private Wealth Management Group LLC boosted its position in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 39 shares during the period. Finally, Truvestments Capital LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $39,000. 83.31% of the stock is owned by institutional investors.
Regeneron Pharmaceuticals Stock Performance
Regeneron Pharmaceuticals stock traded up $5.66 during trading on Wednesday, hitting $685.66. The stock had a trading volume of 637,982 shares, compared to its average volume of 936,789. The stock's 50 day moving average is $702.67 and its two-hundred day moving average is $889.08. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The stock has a market cap of $74.96 billion, a price-to-earnings ratio of 17.91, a price-to-earnings-growth ratio of 2.26 and a beta of 0.08. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $11.86 EPS. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.51%.
Analysts Set New Price Targets
REGN has been the subject of a number of research analyst reports. Sanford C. Bernstein lowered their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. TD Cowen lowered their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research report on Tuesday, February 4th. Bernstein Bank cut their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Robert W. Baird lowered their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a report on Wednesday, February 5th. Finally, StockNews.com lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 4th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $973.13.
Check Out Our Latest Stock Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Profile
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Stories
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
